Osimertinib (AZD9291), an irreversible 3rd generation TKI,...

European Journal of Cancer 2016 / 12 Vol. 69

Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)

Ward, R., Ashton, S., Bianco, A., Colclough, N., Cross, D., Cuomo, E., Finlay, M.R.V., Floch, N., Fitzek, M., Martin, M., Menard, L., McKerrecher, D., O'Neill, D., Orme, J., Talbot, V., Staniszewska,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
69
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(16)32698-3
Date:
December, 2016
File:
PDF, 52 KB
english, 2016
Conversion to is in progress
Conversion to is failed